A Prospective, Multicenter, Single-arm Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced Non-small Cell Lung Cancer With EGFR 21L858R Mutation
Latest Information Update: 30 Oct 2023
At a glance
- Drugs Aumolertinib (Primary) ; Catequentinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ALWAYS
- 24 Oct 2023 New trial record
- 22 Oct 2023 Status changed from completed to recruiting.
- 12 Sep 2023 Results presented at the 24th World Conference on Lung Cancer